| Patient Assistance Programs for Tumor Necrosis Factor Inhibitors | ||||||
|---|---|---|---|---|---|---|
| Drug | Manufacturer | Approval | Ships to | FPL limit | PAP info | Application |
| Adalimumab (Humira®) | Abbvie | PP/PA | Patient or doctor | < 600% | Link | Link (online and pdf) |
| Certolizumab (Cimzia®) | UHC | PP/PA | Patient | < 500% | Link | Link (online) |
| Etanercept (Enbrel®) | Amgen | PP/PA | Patient | < 500% | Link | Link (pdf) |
| Golimumab (Simponi®) | Janssen | PA | Pharmacy | < 400% | Link | Link (pdf) |
| Infliximab (Remicade®) | Janssen | PP/PA | IV infusion Doctor's office |
< 400% | Link | Link (pdf) |
| Patient Assistance Programs for IL-17, IL-23, and IL-12/23 Inhibitors | ||||||
|---|---|---|---|---|---|---|
| Drug | Manufacturer | Approval | Ships to | FPL limit | PAP info | Application |
| Brodalumab (Siliq®) | Ortho | PP | Patient | < 400% | Link | Link (pdf) |
| Ixekizumab (Taltz®) | Lilly | PP/PA | Patient or Doctor | < 500% | Link | Link (online and pdf) |
| Secukinumab (Cosentyx®) | Novartis | PP/PA | Patient | < 570% | Link | Link (pdf) |
| Guselkumab (Tremfya®) | Janssen | PP/PA | Pharmacy | < 400% | Link | Link (pdf) |
| Risankizumab (Skyrizi®) | Abbvie | PP | Patient or Doctor | < 600% | Link | Link (online and pdf) |
| Tildrakizumab (Ilumya™) | Sun Pharma | PP | Doctor | < 400% | Link | Link (pdf) |
| Ustekinumab (Stelara®) | Janssen | PP/PA | Pharmacy or Doctor | < 400% | Link | Link (pdf) |
| Apremilast (Otezla®) Patient Assistance Program | ||||||
|---|---|---|---|---|---|---|
| Drug | Manufacturer | Approval | Ships to | FPL limit | PAP info | Application |
| Apremilast (Otezla®) | Amgen | PP/PA | Patient | < 392% | Link | Link (pdf) |
